These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [What are waiting for chemotherapy in urology (author's transl)].
    Author: Benoit G, Boccon-Gibod L, Debre B, Steg A.
    Journal: Sem Hop; ; 57(25-28):1228-37. PubMed ID: 6266046.
    Abstract:
    The place of chemotherapy inthe treatment of urological cancers remains imprecise. According to numerous publications, all urological cancers should benefit from chemotherapy. This review's goal is to point out the benefits that may be obtained with this type of treatment. Reduction of tumor volume, improvement of quality of survival, length of survival and toxic side effects are taken into account. Two different situations are considered: cases in which chemotherapy has proved to be efficient and should be prescribed, and, in most cases, situations in which chemotherapy is designed to help finding active drug and define efficient therapeutic protocols. This can only be indicated when prospective randomised studies are done in specialised centers with the collaboration of urologists and radiotherapists.
    [Abstract] [Full Text] [Related] [New Search]